Skip to content

A randomized controlled clinical study on the effectiveness and safety of Ciprofol injection in patients undergoing painless artificial abortion surgery

A randomized controlled clinical study on the effectiveness and safety of Ciprofol injection in patients undergoing painless artificial abortion surgery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046737
Enrollment
Unknown
Registered
2021-05-27
Start date
2021-06-01
Completion date
Unknown
Last updated
2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abortion surgery

Interventions

Sponsors

The Affiliated Suzhou Science&Technology Town Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-35 years; 2. American Anesthesiologists (ASA) Grade I-II; 3. Patients with elective painless abortion, single birth, 8-10 weeks of gestation; 4. Body mass index (BMI) 18-30kg/m^2; 5. Vital signs: respiratory rate >=10 and =95% when breathing air; systolic blood pressure (SBP) >=90mmHg and <=160mmHg; diastolic blood pressure (DBP); 6. Able to understand the research process and methods, and voluntarily participate in this research.

Exclusion criteria

Exclusion criteria: 1. Those who have general anesthesia contraindications or have a history of anesthesia accidents in the past; 2. Past history of vaginal delivery; 3. Abnormal uterine anatomy or other serious organic diseases; 4. Severe urinary ketone body 2+ or more in early pregnancy; 5. The patient has a history of artificial abortion within 3 months; 6. Known or suspected allergies or contraindications to propofol injection, cyclopofol injection excipients, benzodiazepines, opioids, muscle relaxants, etc.; 7. Patients with acute upper respiratory tract infection, asthma attack or acute severe throat disease; 8. Have a history of gastrointestinal diseases: gastrointestinal retention, active bleeding, possible reflux and aspiration, etc.; 9. Respiratory insufficiency, obstructive lung disease, difficult airway or difficult tracheal intubation (modified Markov score is III or IV); 10. Uncontrolled hypertension, hypotension and diabetes; 11. Severe arrhythmia, heart failure, unstable angina, myocardial infarction, etc.; 12. Severe liver dysfunction or severe renal insufficiency; 13. History of alcoholism or drug dependence; 14. Abuse or long-term use of narcotic, sedative, and analgesic drugs; 15. Those who have a history of mental illness; 16. Those who have participated in any drug clinical trial within 1 month before screening; 17. The investigator believes that there are any other subjects who are not suitable to participate in this trial.

Design outcomes

Primary

MeasureTime frame
Anesthesia induction success rate;

Countries

China

Contacts

Public ContactLi Hua

The Affiliated Suzhou Science&Technology Town Hospital of Nanjing Medical University

huali0512@163.com+86 17715187078

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026